🔗 Share this article

As the US continues making historic revisions to its vaccination schedules, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning Covid vaccines in the pandemic and has zeroed in on alleged fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders were set to announce sweeping changes to the childhood immunization program earlier this month, bringing the US with the Danish vaccine program, according to reports – a major change that would place the US out of step with many the world with little proof for benefit. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to present at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the office this calendar year.

Consolidating Power at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has often pushed for halting certain childhood immunization guidelines in the US in order to be more similar to Denmark, a society with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – typically the purview of Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Qualifications

The appointee has little discernible track record in drug development, approval processes or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who ran CBER have had.”

This division has an enormous range of responsibilities at the FDA, the former commissioner emphasized.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office authorizes a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and every single one need to be managed,” Dr. Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial management component to the job, which supervises in excess of 5,000 staff members. “It is a huge leadership role, if you execute it properly,” she concluded.

Response and Contentious Programs

When asked about questions about Dr. Høeg's qualifications and whether this selection signifies more teamwork among FDA leaders on vaccines, a press secretary said that the “concerns are based on flawed presumptions”.

“Her experience aligns with the duties of her role,” the representative explained, noting the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious rapid therapy clearance system that apparently concerned her predecessors. “By what process are these medications being chosen for this voucher program? Who makes the decisions?” Howard asked. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of pharmaceuticals, aside from vaccines.”

Documented Past Work on Immunizations

With vaccines, Høeg has a more established, if problematic, track record, critics observe. She authored a research paper using unconfirmed crowd-sourced reports to estimate the rate of myocarditis after COVID-19 vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the new federal leadership encompassed altering guidelines for new vaccines and discontinuing “optional” immunizations, she said post-election on a audio program. At the agency, Dr. Høeg has according to sources suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an thorough true believer who begins with her preconceived notions and tailors the evidence to fit the science in a highly disingenuous, dishonest fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of other dissenters, {like|